跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2019-001431-31-BE
EUCTR2019-001431-31-BE进行中（未招募）1 期

A Phase 2 Study Assessing the Safety and Efficacy of AT-527 in Combination with Daclatasvir in Subjects with Chronic HCV Infection

Atea Pharmaceuticals, Inc.0 个研究点目标入组 10 人开始时间: 2019年4月18日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
10
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Willing and able to provide written informed consent.
  • •2. Male or female subjects between 18 and 65 years of age, inclusive (or the legal age of consent per local regulations).
  • •3. Body mass index (BMI) of 18-35 kg/m2, inclusive.
  • •4. QTcF interval = 450 ms for males and = 460 ms for females at Screening. Note: The mean of the triplicate should be used to assess the QTcF.
  • •5. Male subjects and female subjects of childbearing potential must agree to use protocol specified methods of contraception as described in Section 5.10.
  • •6. Females must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day 1 prior to dosing.
  • •7. Male subjects must agree not to donate sperm from the first dose through 90 days after the last dose of study drugs.
  • •8. Subjects must not consume grapefruit or grapefruit juice within 7 days of reporting to the clinic on Day 1 and must agree not to do so through the end of the treatment period.
  • •9. Subjects may be treatment-naïve or treatment-experienced (except for prior NS5A inhibitor recipients, exclusion 4), classified as one of the following:
  • •Treatment-naïve: Never exposed to approved or experimental HCV DAA(s) or interferon with or without ribavirin
  • •Treatment-experienced: Prior treatment failure to approved or experimental HCV DAA(s) and/or interferon with or without ribavirin; prior treatment must have been completed or discontinued more than three months prior to Screening for the present study
  • •10. Subjects must have HCV genotype 1 documented at Screening.
  • •11. Documented medical history compatible with chronic hepatitis C, including any one of the following:
  • •anti-HCV antibody or HCV RNA positive at least once prior to Screening, OR
  • •HCV infection likely acquired from exposures more than 6 months prior to Screening
  • •12. HCV RNA bigger or equal to 10,000 IU/mL at Screening.
  • •13. Subject is, in the opinion of the investigator, willing and able to comply with the study drug regimen and all other study requirements
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 15
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •1.Female subject is pregnant or breastfeeding.
  • •2.Co-infected with hepatitis B virus and/or human HIV.
  • •3.Abuse of alcohol and/or illicit drug use that could interfere with adherence to study requirements as judged by the investigator. A positive screen for drug(s) of abuse will exclude subjects unless it can be explained by a prescribed medication and approved by the investigator.
  • •4.Prior exposure to any HCV NS5A inhibitor.
  • •5.Concomitant use of any known major inhibitor or inducer of cytochrome P450 (CYP) 3A4. A washout period of at least 5 half-lives of the CYP 3A4 drug must be observed prior to study drug dosing, if the investigator feels that the drug can be safely discontinued or substituted for the duration of the study.
  • •6.Concomitant use of any known major inhibitor or inducer of P-glycoprotein (P- gp; e.g. rifampin, St. John’s Wort) or breast cancer resistance protein (BCRP).
  • •A washout period of at least 5 half-lives of the drug must be observed prior to study drug dosing, if the investigator feels that the drug can be safely discontinued or substituted for the duration of the study.
  • •7.Concomitant use of herbal or natural supplements A washout period of at least 7 days must be observed prior to study drug dosing, if the investigator feels that they can be safely discontinued or substituted for the duration of the study.
  • •8.Concomitant use of acid blockers. A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that the drug can be safely discontinued or substituted for the duration of the study. Antacids will be allowed during the study, except ±4 h of dosing.
  • •9.Concomitant use of any other medication that is contraindicated for use with daclatasvir according to its prescribing information. A washout period of at least 5 half-lives must be observed prior to study drug dosing, if the investigator feels that the drug can be safely discontinued or substituted for the duration of the study.
  • •10.Requires frequent or prolonged use of systemic corticosteroids or other immunosuppressive drugs
  • •Topical or inhaled corticosteroids are permitted.
  • •11.Use of other investigational drugs within 30 days of dosing, or plans to enroll in another clinical trial of an investigational agent while participating in the present study.
  • •12.Subject with intestinal malabsorption (e.g., structural defects, digestive failure or enzyme deficiencies with the exception of lactose intolerance).
  • •13.Subject with known allergy to the study medication(s) or any of their components.
  • •14.Prior evidence of cirrhosis, defined by any one of the following:
  • •i.Liver biopsy showing cirrhosis
  • •ii.Transient elastography (FibroScan®) with a result of > 12.5 kPa
  • •Absence of cirrhosis may be confirmed by one of the above methods, if available within 1 year of Screening. Otherwise, transient elastography assessment may be done during Screening.
  • •15.History or signs of decompensated liver disease: ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal hypertension or hepatic insufficiency.
  • •16.History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC.
  • •17.Active clinically significant diseases including:
  • •Primary or secondary causes of liver disease other than hepatitis C (e.g., hemochromatosis, alpha-1 antitrypsin deficiency, Wilson’s Disease, cholangitis).
  • •Malignant disease or suspicion or history of malignant disease wi

研究者

相似试验

进行中（未招募）
不适用
A Phase 2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer - Phase 2 Study evaluating safety and efficacy of ABT-751 and Docetaxel in NSCLC
EUCTR2006-002838-38-GBAbbott GmbH & Co. KG180
进行中（未招募）
1 期
Phase 2 Study of Idelalisib in Indolent B-Cell Non-Hodgkin LymphomaIndolent B-Cell Non-Hodgkin LymphomaMedDRA version: 20.0Level: PTClassification code 10029601Term: Non-Hodgkin's lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2010-022155-33-DEGilead Sciences, Inc.120
进行中（未招募）
不适用
Efficacy and Safety of SM101 in the Treatment of IgA NephropathyIgA NephropathyMedDRA version: 18.0Level: PTClassification code 10021263Term: IgA nephropathySystem Organ Class: 10038359 - Renal and urinary disorders
EUCTR2015-002345-64-CZBaxalta Innovations GmbH51
进行中（未招募）
1 期
Phase 2 Study of Idelalisib in Indolent B-Cell Non-Hodgkin LymphomaIndolent B-Cell Non-Hodgkin LymphomaMedDRA version: 20.0 Level: PT Classification code 10029601 Term: Non-Hodgkin's lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2010-022155-33-GBGilead Sciences, Inc.125
招募中
不适用
A Phase 2 Study to Assess the Efficacy and Safety of CMX-020 in Treating Osteoarthritis.osteoarthritis
ACTRN12616001435471Cytometix A90